

**APOA1 Antibody (N-term) Blocking Peptide**  
**Synthetic peptide**  
**Catalog # BP7414a****Specification**

---

**APOA1 Antibody (N-term) Blocking Peptide - Product Information**Primary Accession [P02647](#)**APOA1 Antibody (N-term) Blocking Peptide - Additional Information**

Gene ID 335

**Other Names**

Apolipoprotein A-I, Apo-AI, ApoA-I, Apolipoprotein A1, Proapolipoprotein A-I, ProapoA-I, Truncated apolipoprotein A-I, Apolipoprotein A-I(1-242), APOA1

**Target/Specificity**

The synthetic peptide sequence used to generate the antibody [AP7414a](/products/AP7414a) was selected from the N-term region of human APOA1. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**APOA1 Antibody (N-term) Blocking Peptide - Protein Information**Name APOA1 ([HGNC:600](#))**Function**

Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility.

**Cellular Location**

Secreted.

**Tissue Location**

Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette

smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease

### **APOA1 Antibody (N-term) Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

### **APOA1 Antibody (N-term) Blocking Peptide - Images**

### **APOA1 Antibody (N-term) Blocking Peptide - Background**

Apolipoprotein A-I, is the major protein component of high density lipoprotein (HDL) in plasma. APOA1 promotes cholesterol efflux from tissues to the liver for excretion, and it is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. Defects in the APOA1 gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.

### **APOA1 Antibody (N-term) Blocking Peptide - References**

Simo,R., Arch. Ophthalmol. 126 (8), 1076-1081 (2008)Shanker,J., Lipids Health Dis 7, 33 (2008)Brewer,H.B. Jr., Biochem. Biophys. Res. Commun. 80 (3), 623-630 (1978)